×

Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.

The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

LOS ANGELES, Calif., Nov. 11, 2019 /PRNewswire/ -- Four new Prostate Cancer Foundation (PCF) Centers of Excellence (COEs) have joined the PCF's dedicated network of centers executing the ambitious mission of improving the...Read More

THE PROSTATE CANCER FOUNDATION ANNOUNCES A COLLABORATIVE GRANTS PROGRAM IN PROSTATE CANCER RESEARCH

THE PROSTATE CANCER FOUNDATION ANNOUNCES A COLLABORATIVE GRANTS PROGRAM IN PROSTATE CANCER RESEARCH

LOS ANGELES, Calif., September 26, 2019 – The Prostate Cancer Foundation (PCF) today announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through...Read More

07-13_BreakingNews_FeaturedImg745x510

FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer

September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Apalutamide has previously...Read More

LIB_PressRelease_745x510_090419

The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue

LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September...Read More

PCFChallengeAwds_FeaturedImg745x510

The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners

The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research...Read More

07-13_BreakingNews_FeaturedImg745x510

FDA Approves Bayer’s Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic...Read More

Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine

Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine

Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of...Read More

ArulChinnaiyan_745x510

Newly defined cancer driver is Fast, Furious and Loud

Original Press Release Issued by: University of Michigan Medicine ANN ARBOR, Michigan — The Fast and the Furious movie franchise meets the Fast N’ Loud television series to define an...Read More

HRC_w_fieldBG_745x510

THE PROSTATE CANCER FOUNDATION AND MAJOR LEAGUE BASEBALL KICK OFF 24th ANNUAL HOME RUN CHALLENGE ON JUNE 1st

One in 9 U.S. men will be diagnosed with prostate cancer which is equivalent to at least one player on a baseball team One man dies from prostate cancer every...Read More

Black men less likely than nonblack patients to adopt active surveillance for low-risk prostate cancer

Black men less likely than nonblack patients to adopt active surveillance for low-risk prostate cancer

Original Press Release Issued by: Dana-Farber Cancer Institute Overall active surveillance rates are up, though the increase is significantly smaller for black patients Black men may be deterred by both socioeconomic...Read More